A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

Trial Profile

A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Poly ICLC (Primary) ; Keyhole limpet haemocyanin; Montanide ISA-51; Peptide vaccines
  • Indications Glioblastoma
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 29 Aug 2017 Planned number of patients changed from 6 to 30.
    • 29 Aug 2017 Status changed from not yet recruiting to recruiting.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top